---
schema_version: "secwatch.filing_event.v1"
accession: "0001657312-24-000011"
form_type: "8-K"
ticker: null
cik: "0001657312"
company_name: "Verona Pharma plc"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:12:36.239537+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verona Pharma reports Q1 net loss $25.8M; PDUFA for ensifentrine June 26, secures $650M financing

## Summary
- Net loss $25.8M for Q1 2024 vs $16.7M in Q1 2023; SG&A costs rose to $20.4M on launch prep.
- Cash and equivalents $254.9M at March 31, 2024; new $650M strategic financing available.
- PDUFA target date for ensifentrine (COPD) is June 26, 2024; no advisory committee planned.
- R&D expenses fell to $6.8M (Q1 2023: $12.6M) as ENHANCE Phase 3 program completed in 2023.
- If approved, commercial launch in US expected Q3 2024; Phase 2 trials in COPD combo and bronchiectasis planned H2 2024.

## SEC filing metadata
- accession: 0001657312-24-000011
- form_type: 8-K
- cik: 0001657312
- company_name: Verona Pharma plc
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1657312/000165731224000011/0001657312-24-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1657312/000165731224000011/vrna-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001657312-24-000011
- JSON: https://secwatch.observer/filing/0001657312-24-000011.json
- Plain text: https://secwatch.observer/filing/0001657312-24-000011.txt

## Key facts
- Earnings Releases
  Verona Pharma plc reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: Verona Pharma plc announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1657312/000165731224000011/0001657312-24-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.